Drugs / RSS0343
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07696091 | Jul → Sep 2026 overdue | chronic obstructive pulmonary disease, chronic rhinosinusitis | Reistone Biopharma Company Limited | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07289464 | Jan → Sep 2026 overdue | bronchiectasis | Reistone Biopharma Company Limited | Recruiting | No outcome recorded |
| Phase 1 | NCT07101965 | Apr → Nov 2024 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07349524 | Mar 2026 → Mar 2028 expected | chronic obstructive pulmonary disease | Reistone Biopharma Company Limited | Recruiting | No outcome recorded |
| Phase 2 | NCT06775340 | Jan 2025 → Nov 2027 expected | childhood onset asthma | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSS0343 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06775340 ↗ |
| Route | Oral | “RSS0343 tablets, oral;” NCT06775340 ↗ |